Healthcare
Insights into barriers that cause cancer patients not to enroll in specific trials are helping pharmaceutical companies adjust their trial designs and assumptions.
Several weeks ago, a podcast published on the Journal of the American Medical Association’s website featured a statement that questioned whether racism exists in medicine, a statement that spurred a barrage of complaints from concerned readers, scientists and even public opinion leaders.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
If you’re one of the 17% of Americans that have been fully vaccinated against SARS-CoV-2, you are probably feeling some level of relief. But the CDC warns not to throw your mask away just yet.
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and diagnostics are available. They’re just not used.
Will We Need COVID-19 Vaccines Every Year? Although the jury is still out, a study out of Charité – Universitätsmedizin Berlin suggests that the answer is yes for a few years, but may be unnecessary after a few years post-pandemic.
The Orphan Drug Act passed in 1983 and granted tax credits, subsidies and fee waivers for rare disease drug development in areas of unmet need. It also guaranteed seven years of market exclusivity following approval, longer than the five years typical for most new chemical entities.
A global pandemic has left life sciences companies with giant targets on their backs for cyberattacks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES